Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRGN-3005

Cell therapy (CAR-T) · Kills target cells, directed at MUC16 (CA125) (MUC16) · developed by Precigen

Phase 1 Most advanced trial
PGEN Developer
1 Registered trials

What is PRGN-3005?

PRGN-3005 is an autologous T-lymphocyte preparation genetically modified with the Sleeping Beauty transposon system to express an anti-MUC16 chimeric antigen receptor, a membrane-bound IL-15 and a safety switch. The CAR-T cells bind MUC16-expressing tumor cells to induce selective toxicity. It is studied in platinum-resistant, recurrent and refractory ovarian, fallopian tube and primary peritoneal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
MUC16 (CA125) (MUC16) (antigen)
Mechanism
Kills target cells, directed at MUC16 (CA125) (MUC16)
Pathways
IL-15 signaling
Therapy area
Oncology
Developer
Precigen, Inc (PGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03907527 Phase 1 Platinum-Resistant Fallopian Tube Carcinoma Active not recruiting PGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Ovarian CarcinomaRefractory Primary Peritoneal CarcinomaStage III Fallopian Tube Cancer AJCC V8Stage III Ovarian Cancer AJCC V8Stage III Primary Peritoneal Cancer AJCC V8Stage IIIA Fallopian Tube Cancer AJCC V8Stage IIIA Ovarian Cancer AJCC V8

Other drugs acting on MUC16

More from Precigen

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PGEN page.

Follow PGEN, the company behind PRGN-3005

See PGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.